Lineage Cell Therapeutics Inc. — Director's Dealing 2019

Jul 4, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2019-07-01

Reporting Person: KINGSLEY ALFRED D (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-07-01	Stock Option (Right to Buy)	$1.03	A	70000	Acquired	2029-06-30	Common Shares (70000)	Direct

Footnotes

F1: Will become exercisable on June 30, 2020, based upon continued service on the board of directors.